C. Clara Dees, A. Akhmetshina, P. Zerr, N. Reich, K. Palumbo, A. Horn, A. Jüngel, C. Beyer, G. Krönke, J. Zwerina, R. Reiter, N. Alenina, L. Maroteaux, S. Gay, G. Schett, O. Distler and J. H. Distler. Platelet-derived serotonin links vascular disease and tis- sue fibrosis. The Journal of Experimental Medicine, 2011, 208(5): 961-972.
被以下文章引用:
-
标题:
5-羟色胺与硬皮病Serotonin and Scleroderma
作者:
黄建国, 龚启英, 黄朝頔, 李桂明
关键字:
5-羟色胺, 硬皮病Serotonin; Scleroderma
期刊名称:
《Hans Journal of Medical Cosmetology》, Vol.1 No.1, 2013-10-14
摘要:
硬皮病是自身免疫性疾病之一，以血管功能障碍、炎症和皮肤硬化为特征。5-羟色胺(5-HT)作为血管活性胺类物质，炎症介质能刺激真皮成纤维细胞增殖；5-HT/5-HT2B信号通过调控血管损伤和血小板活性从而与皮肤组织纤维化有关联。临床上采用5-HT3受体抑制剂托烷司琼(tropisetron)治疗硬皮病患者取得明显效果。研究5-HT与硬皮病的关系对治疗硬皮病将开辟一条新的途径。
Scleroderma is one of the autoimmune diseases characterized by inflammation, vascular dysfunction and skin sclerosis. As the vasoactive amine substances and inflammatory mediators, serotonin (5-HT) can stimulate the dermal fibroblast proliferation; 5-HT/5-HT2B signal are associated with skin tissue fibrosis through regulating vascular injury and platelet activity. The clinical application of tropisetron (5-HT3 receptor inhibitor) obtains obvious effects in the treatment of patients with scleroderma. Study on the relationship between 5-HT and scleroderma will inaugurate a new way for the treatment of scleroderma.